Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd.

This study is an open-label, multicenter, randomized, proof-of-concept, global Phase II platform study designed to evaluate the efficacy and safety of multiple innovative combination therapies in patients with HNSCC. The flexible clinical study design allows for early termination of the study of the trial treatment group with limited clinical efficacy or unacceptable toxicity based on interim data, as well as the introduction of new trial treatment groups into the platform study when innovative combination therapies become available, and the adjustment of the patient subgroup population being studied within the trial treatment group. Cohort 1 of Substudy 01 is designed to evaluate the efficacy and safety of innovative combination therapies as first-line treatment for subjects with r/m HNSCC. Cohort 1 (treatment groups A and B) uses a randomized design to evaluate the efficacy and safety of domvanalimab and sepalizumab combined with platinum-based doublet chemotherapy versus sepalizumab combined with platinum-based doublet chemotherapy. Cohort 2 of Substudy 01 is a biomarker cohort designed to evaluate the mechanism of action of innovative combination therapies and the efficacy and safety of treatment. Cohort 2 is planned for this study, and the sponsor will decide whether to enable this cohort at its discretion.

To evaluate the efficacy and safety of liposomal amphotericin B for injection (trademark: Amphotericin B®) in Chinese adults and pediatric patients aged 1 month to 18 years.

Objective 1: To record the number of people who use PrEP once a day among 3,200 high-risk MSM and college-age youth in two Chinese cities. Objective 2: To obtain HIV/STI risk behaviors and knowledge, perceptions, and practices regarding sexual behaviors and PrEP use through questionnaire surveys among 3,200 high-risk MSM and college-age youth in two Chinese cities. Objective 3: To obtain data on syphilis and HIV prevalence among 3,200 MSM and college-age youth and syphilis, gonorrhea, chlamydia, and HIV prevalence among 1,200 PrEP users in two Chinese cities. Objective 4: To determine retention, adherence, and characteristics of 1,200 PrEP users at 6 and 12 months. Objective 5: To evaluate the experience of the PrEP WeChat mini-program intervention among MSM and college-age youth through in-depth interviews with selected participants (n = 30).